AU2003248893A8 - Compositions and methods for the treatment of parkinson's disease and tardive dyskinesias - Google Patents

Compositions and methods for the treatment of parkinson's disease and tardive dyskinesias

Info

Publication number
AU2003248893A8
AU2003248893A8 AU2003248893A AU2003248893A AU2003248893A8 AU 2003248893 A8 AU2003248893 A8 AU 2003248893A8 AU 2003248893 A AU2003248893 A AU 2003248893A AU 2003248893 A AU2003248893 A AU 2003248893A AU 2003248893 A8 AU2003248893 A8 AU 2003248893A8
Authority
AU
Australia
Prior art keywords
parkinson
disease
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
AU2003248893A
Other versions
AU2003248893A1 (en
Inventor
Jodi Nelson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alpha Research Group LLC
Original Assignee
Alpha Research Group LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/192,414 external-priority patent/US20020198231A1/en
Application filed by Alpha Research Group LLC filed Critical Alpha Research Group LLC
Publication of AU2003248893A1 publication Critical patent/AU2003248893A1/en
Publication of AU2003248893A8 publication Critical patent/AU2003248893A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47064-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003248893A 2002-07-09 2003-07-09 Compositions and methods for the treatment of parkinson's disease and tardive dyskinesias Abandoned AU2003248893A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/192,414 US20020198231A1 (en) 1999-07-13 2002-07-09 Compositions and methods for the treatment of Parkinson's disease
US10/192,414 2002-07-09
US47974803P 2003-06-19 2003-06-19
US60/479,748 2003-06-19
PCT/US2003/021463 WO2004004660A2 (en) 2002-07-09 2003-07-09 Compositions and methods for the treatment of parkinson’s disease and tardive dyskinesias

Publications (2)

Publication Number Publication Date
AU2003248893A1 AU2003248893A1 (en) 2004-01-23
AU2003248893A8 true AU2003248893A8 (en) 2004-01-23

Family

ID=30117814

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003248893A Abandoned AU2003248893A1 (en) 2002-07-09 2003-07-09 Compositions and methods for the treatment of parkinson's disease and tardive dyskinesias

Country Status (5)

Country Link
EP (1) EP1581167A4 (en)
JP (1) JP2006514917A (en)
AU (1) AU2003248893A1 (en)
CA (1) CA2531810A1 (en)
WO (1) WO2004004660A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007067714A2 (en) 2005-12-08 2007-06-14 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
CA2642672A1 (en) * 2006-02-16 2007-08-30 The Mclean Hospital Corporation Methods and compositions for the treatment of parkinson's disease
WO2010141712A2 (en) * 2009-06-03 2010-12-09 Marquette University Modulation of kcnq potassium channel activity for treatment of psychiatric disorders and the symptoms thereof
EP2509953B1 (en) * 2009-12-11 2016-03-30 Genecode AS Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators
CN113354581B (en) * 2020-03-06 2023-06-20 华南理工大学 Preparation method and application of chiral chloroquine and phosphate thereof
CN113527201A (en) * 2020-04-14 2021-10-22 瀚海新拓(杭州)生物医药有限公司 Optically active chloroquine and hydroxychloroquine and analogs thereof, preparation method, composition and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5430039A (en) * 1990-09-28 1995-07-04 Cephalon, Inc. Treatment of neurological disorders
US5496836A (en) * 1994-05-05 1996-03-05 Mount Sinai School Of Medicine Of The City University Of New York Use of famotidine and related compounds in the treatment of movement disorders
DE4428199A1 (en) * 1994-08-09 1996-02-15 Univ Ludwigs Albert Use of flunitrazepam and/or chloroquine
CA2416233A1 (en) * 1999-07-13 2001-01-18 Alpha Research Group, Llc Compositions and methods for the treatment of parkinson's disease

Also Published As

Publication number Publication date
CA2531810A1 (en) 2004-01-15
AU2003248893A1 (en) 2004-01-23
JP2006514917A (en) 2006-05-18
EP1581167A4 (en) 2008-10-29
WO2004004660A3 (en) 2005-11-03
EP1581167A2 (en) 2005-10-05
WO2004004660A2 (en) 2004-01-15

Similar Documents

Publication Publication Date Title
TWI340640B (en) Combination, kit and pharmaceutical composition for treatment of parkinson's disease
AU2003223579A8 (en) Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
WO2004030615A8 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004016225A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1571968A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004045516A9 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1571968A4 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1575480A4 (en) Compositions and methods for the treatment of immune related diseases
EP1578367A4 (en) Compositions and methods for the treatment of immune related diseases
EP1572116A4 (en) Compositions and methods for the treatment of immune related diseases
EP1576137A4 (en) Compositions and methods for the treatment of immune related diseases
IL175529A0 (en) Methods and compositions for the treatment of metabolic disorders
WO2004024097A9 (en) Compositions and methods for the treatment of immune related diseases
EP1572091A3 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1572091A4 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004060270A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1553912A4 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2003057160A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1560593A4 (en) Novel composition and methods for the treatment of immune related diseases
ZA200605555B (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular disease
AU2003231252A1 (en) Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
EP1680145A4 (en) Methods and compositions for the treatment of neurological disease
PL371281A1 (en) Methods and compositions for the treatment of eye diseases
AU2003254146A1 (en) Methods for the treatment of parkinson's disease
AU2003248893A8 (en) Compositions and methods for the treatment of parkinson's disease and tardive dyskinesias

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase